Harnessing the Potential of CAR T-Cell Therapy for Multiple Myeloma

Marcie Morris, PharmD, CSP

Multiple myeloma (MM), a blood cancer that develops in plasma cells, can result in low blood counts and weakening of the immune system.¹ According to the National Cancer Institute, MM accounted for approximately 1.8% of new cancer cases in the United States in 2024.² The cause of MM is unknown and there is no cure. Approximately 40% of Americans diagnosed with MM die within 5 years.^2,3

Despite